Particle Data Platform

Treatment future and incentives

55:2456:25 · 61s

Fox flags a worrying trend: pharma invests less in immune-retraining approaches and more in lifelong symptom blockers, shaping allergy care’s direction.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.